Interaction of miltefosine with the lipid and protein components of the erythrocyte membrane

Journal of Pharmaceutical Sciences

Volumn 102, Issue 5, 2013, Pages 1661-1669

  Moreira, Rodrigo Alves ^a   Mendanha, Sebastião Antonio ^a   Hansen, Daiane ^a   Alonso, Antonio ^a  

^a FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

Author keywords

Drug interactions; EPR; Erythrocyte membrane; Lipids; Miltefosine; Nanotechnology; Pharmacokinetics; Proteins; Raft; Spin label

Indexed keywords

LIPID; MILTEFOSINE; SPHINGOMYELIN; THIOL GROUP;

ACT; ARTICLE; BILAYER MEMBRANE; BLOOD LEVEL; CELL MEMBRANE FLUIDITY; CONTROLLED STUDY; ELECTRON SPIN RESONANCE; ERYTHROCYTE GHOST; ERYTHROCYTE MEMBRANE; HEMOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROPHOBICITY; LEISHMANIASIS; LIPID BILAYER; LIPID RAFT; MOLECULAR DYNAMICS; PH; PROTEIN CONFORMATION; PROTEIN CONTENT; SKIN LEISHMANIASIS; VISCERAL LEISHMANIASIS;

EID: 84876322000     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23496     Document Type: Article

References (48)

1. Olliaro PL, Guerin PJ, Gerstl S, Haaskjold AA, Rottingen J-A, Sundar S. 2005. Treatment options for visceral leishmaniasis: A systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis 5:763-774.
2. Pérez-Victoria FJ, Sánchez-Cañete MP, Seifert K, Croft SL, Sundar S, Castanys S, Gamarro F. 2006. Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use. Drug Resist Updat 9:26-39.
3. Bhattacharya SK, Sinha PK, Sundar S, Thakur CP, Jha TK, Pandey K, Das VR, Kumar N, Lal C, Verma N, Singh VP, Ranjan A, Verma RB, Anders G, Sindermann H, Ganguly NK. 2007. Phase 4 trial of miltefosine for the treatment of indian visceral leishmaniasis. J Infect Dis 196:591-598.
4. Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, Luz M, Gutierrez P, Arboleda M, Berman JD, Junge K, Engel J, Sindermann H. 2004. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 38:1266-1272.
5. Soto J, Toledo J, Gutierrez P, Nicholls RS, Padilla J, Engel J, Fischer C, Voss A, Berman J. 2001. Treatment of american cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 33:e57-e61.
6. Mohebali M, Fotouhi A, Hooshmand B, Zarei Z, Akhoundi B, Rahnema A, Razaghian AR, Kabir MJ, Nadim A. 2007. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Trop 103:33-40.
7. Soto J, Toledo J, Valda L, Balderrama M, Rea I, Parra R, Ardiles J, Soto P, Gómez A, Molleda F, Fuentelsaz C, Anders G, Sindermann H, Engel J, Berman J. 2007. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 44:350-356.
8. Dorlo TP, Balasegaram M, Beijnen JH, de Vries PJ. 2012. Miltefosine: A review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemother 67:2576-2597.
9. van der Luit AH, Vink SR, Klarenbeek JB, Perrissoud D, Solary E, Verheij M, van Blitterswijk WJ. 2007. A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells. Mol Cancer Ther 6:2337-2345.
10. Weller K, Artuc M, Jennings G, Friedrichson T, Guhl S, dos Santos RV, Sunder C, Zuberbier T, Maurer M. 2008. Miltefosine inhibits human mast cell activation and mediator release both in vitro and in vivo. J Invest Dermatol 129(2):496-498.
11. Bäumer W, Wlaź P, Jennings G, Rundfeldt C. 2010. The putative lipid raft modulator miltefosine displays immunomodulatory action in T-cell dependent dermal inflammation models. Eur J Pharmacol 628(1-3):226-232.
12. Gajate C, Mollinedo F. 2001. The antitumor ether lipid ET-18-OCH(3) induces apoptosis through translocation and capping of Fas/CD95 into membrane rafts in human leukemic cells. Blood 98:3860-3863.
13. Gajate C, Del Canto-Jañez E, Acuña AU, Amat-Guerri F, Geijo E, Santos-Beneit AM, Veldman RJ, Mollinedo F. 2004. Intracellular triggering of Fas aggregation and recruitment of apoptotic molecules into Fas-enriched rafts in selective tumor cell apoptosis. J Exp Med 200:353-365.
14. Gajate C, Mollinedo F. 2007. Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood 109:711-719.
15. Ausili A, Torrecillas A, Aranda FJ, Mollinedo F, Gajate C, Corbalán-García S, de Godos A, Gómez-Fernández JC. 2008. Edelfosine is incorporated into rafts and alters their organization. J Phys Chem B 112:11643-11654.
16. Mollinedo F, de la Iglesia-Vicente J, Gajate C, Estella-Hermoso de Mendoza A, Villa-Pulgarin JA, Campanero MA, Blanco-Prieto MJ. 2010. Lipid raft-targeted therapy in multiple myeloma. Oncogene 29:3748-3757.
17. Paris C, Loiseau PM, Bories C, Bréard J. 2004. Miltefosine induces apoptosis-like death in leishmania donovani promastigotes. Antimicrob Agents Chemother 48:852-859.
18. Verma NK, Singh G, Dey CS. 2007. Miltefosine induces apoptosis in arsenite-resistant Leishmania donovani promastigotes through mitochondrial dysfunction. Exp Parasitol 116:1-13.
19. Marinho FA, Gonçalves KC, Oliveira SS, Oliveira AC, Bellio M, d'Avila-Levy CM, Santos AL, Branquinha MH. 2011. Miltefosine induces programmed cell death in Leishmania amazonensis promastigotes. Mem Inst Oswaldo Cruz 106:507-509.
20. Varela-M RE, Villa-Pulgarin JA, Yepes E, Müller I, Modolell M, Muñoz DL, Robledo SM, Muskus CE, López-Abán J, Muro A, Vélez ID, Mollinedo F. 2012. In vitro and in vivo efficacy of ether lipid edelfosine against Leishmania spp. and SbV-resistant parasites. PLoS Negl Trop Dis 6:e1612.
21. Alonso L, Mendanha SA, Marquezin CA, Berardi M, Ito AS, Acuña AU, Alonso A. 2012. Interaction of miltefosine with intercellular membranes of stratum corneum and biomimetic lipid vesicles. Int J Pharm 434:391-398.
22. Dorlo TP, Huitema AD, Beijnen JH, de Vries PJ. 2012. Optimal dosing of miltefosine in children and adults with visceral leishmaniasis. Antimicrob Agents Chemother 56:3864-3872.
23. Dorlo TP, Balasegaram M, Lima MA, de Vries PJ, Beijnen JH, Huitema AD. 2012. Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine. J Antimicrob Chemother 67:1996-2004.
24. Dorlo TP, van Thiel PP, Huitema AD, Keizer RJ, de Vries HJ, Beijnen JH, de Vries PJ. 2008. Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. Antimicrob Agents Chemother 52:2855-2860.
25. Samuel BU, Mohandas N, Harrison T, McManus H, Rosse W, Reid M, Haldar K. 2001. The role of cholesterol and glycosylphosphatidylinositol-anchored proteins of erythrocyte rafts in regulating raft protein content and malarial infection. J Biol Chem 276:29319-29329.
26. Murphy SC, Samuel BU, Harrison T, Speicher KD, Speicher DW, Reid ME, Prohaska R, Low PS, Tanner MJ, Mohandas N, Haldar K. 2004. Erythrocyte detergent-resistant membrane proteins: Their characterization and selective uptake during malarial infection. Blood 103:1920-1928.
27. Ciana A, Balduini C, Minetti G. 2005. Detergent-resistant membranes in human erythrocytes and their connection to the membrane-skeleton. J Biosci 30:317-328.
28. Crepaldi Domingues C, Ciana A, Buttafava A, Balduini C, de Paula E, Minetti G. 2009. Resistance of human erythrocyte membranes to Triton X-100 and C12E8. J Membr Biol 227:39-48.
29. Goñi FM, Alonso A, Bagatolli LA, Brown RE, Marsh D, Prieto M, Thewalt JL. 2008. Phase diagrams of lipid mixtures relevant to the study of membrane rafts. Biochim Biophys Acta 1781:665-684.
30. McQuaw CM, Zheng L, Ewing AG, Winograd N. 2007. Localization of sphingomyelin in cholesterol domains by imaging mass spectrometry. Langmuir 23:5645-5650.
31. Veatch SL, Keller SL. 2005. Miscibility phase diagrams of giant vesicles containing sphingomyelin. Phys Rev Lett 94:148101.
32. Alonso A, Meirelles NC, Tabak M. 1995. Effect of hydration upon the fluidity of intercellular membranes of stratum corneum: An EPR study. Biochim Biophys Acta 1237:6-15.
33. Alonso A, Gonçalves dos Santos J, Tabak M. 2000. Stratum corneum protein mobility as evaluated by a spin label maleimide derivative. Biochim Biophys Acta 1478:89-101.
34. Gonçalves do Couto S, de Souza Oliveira M, Alonso A. 2005. Dynamics of proteins and lipids in the stratum corneum: Effects of percutaneous permeation enhancers. Biophys Chem 116:23-31.
35. Anjos JLV, Santiago PS, Tabak M, Alonso A. 2011. On the interaction of bovine serum albumin with ionic surfactants: Temperature induced EPR changes of a maleimide nitroxide reflect local protein dynamics and probe solvent accessibility. Colloids Surf B Biointerfaces 88:463-470.
36. de Queirós WP, de Sousa Neto D, Alonso A. 2005. Dynamics and partitioning of spin-labeled stearates into the lipid domain of stratum corneum. J Control Release 106:374-385.
37. dos Anjos JLV, Neto DdS, Alonso A. 2007. Effects of ethanol/l-menthol on the dynamics and partitioning of spin-labeled lipids in the stratum corneum. Eur J Pharm Biopharm 67:406-412.
38. Alonso A, Queiroz CS, Magalhães AC. 1997. Chilling stress leads to increased cell membrane rigidity in roots of coffee (Coffea arabica L.) seedlings. Biochim Biophys Acta 1323:75-84.
39. Queiroz CGS, Alonso A, Mares-Guia M, Magalhães AC. 1998. Chilling-induced changes in membrane fluidity and antioxidant enzyme activities in Coffea arabica L. roots. Biol Plantarum 41:403-413.
40. Desoti VC, Lazarin-Bidóia D, Sudatti DB, Pereira RC, Alonso A, Ueda-Nakamura T, Dias Filho BP, Nakamura CV, de Oliveira Silva S. 2012. Trypanocidal action of (-)-elatol involves an oxidative stress triggered by mitochondria dysfunction. Mar Drugs 10:1631-1646.
41. Mendanha SA, Moura SS, Anjos JLV, Valadares MC, Alonso A. 2013. Toxicity of terpenes on fibroblast cells compared to their hemolytic potential and increase in erythrocyte membrane fluidity. Toxicol In Vitro 27:323-329.
42. Jost PC, Griffith OH, Capaldi RA, Vanderkooi G. 1973. Evidence for boundary lipid in membranes. Proc Natl Acad Sci USA 70:480-384.
43. Turro NJ, Lei X-G, Ananthapadmanabhan KP, Aronson M. 1995. Spectroscopic probe analysis of protein-surfactant interactions: The BSA/SDS system. Langmuir 11:2525-2533.
44. Tabak M, Sousa Neto Dd, Salmon CEG. 2006. On the interaction of bovine serum albumin (BSA) with cethyltrimethyl ammonium chloride surfactant: Electron paramagnetic resonance (EPR) study. Braz J Phys 36:83-89.
45. Rakotomanga M, Loiseau PM, Saint-Pierre-Chazalet M. 2004. Hexadecylphosphocholine interaction with lipid monolayers. Biochim Biophys Acta 1661:212-218.
46. Widmer F, Wright LC, Obando D, Handke R, Ganendren R, Ellis DH, Sorrell TC. 2006. Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis. Antimicrob Agents Chemother 50(2):414-421.
47. Croft SL, Seifert K, Duchêne M. 2003. Antiprotozoal activities of phospholipid analogues. Mol Biochem Parasitol 126:165-172.
48. Sánchez-Cañete MP, Carvalho L, Pérez-Victoria FJ, Gamarro F, Castanys S. 2009. Low plasma membrane expression of the miltefosine transport complex renders Leishmania braziliensis refractory to the drug. Antimicrob Agents Chemother 53:1305-1313.